Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of linerixibat for cholestatic pruritus in primary biliary cholangitis
2021-000007-21Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cholestatic pruritus and primary biliary cholangitis (PBC) comparing Linerixibat with Placebo (2 arms). Primary endpoint: Change from baseline in monthly itch scores over 24 weeks. Started Jun 2021; status: completed.
02
Drugs
linerixibat
03
Conditions
cholestatic pruritusprimary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2021-000007-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000007-21.